Trial reportDrug design, development and therapy2026
Preliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the effects of hydrogen-oxygen inhalation on nodule diameter and peripheral blood inflammatory factors in patients with small pulmonary nodules (SPNs), and to further analyze its efficacy in the smoking subgroup. The primary endpoint was the change in pulmonary nodule diameter before and after intervention; secondary endpoints included alterations in serum IL-6, CRP, peripheral blood neutrophil count, and Mayo malignant transformation risk score. Methods: A total of 59 patients with SPNs confirmed by chest CT were enrolled and randomly divided into the observation group (hydrogen-oxygen inhalation, n=30) and control group (air inhalation, n=29). The intervention lasted 14 consecutive days, and all indicators were re-examined at 3-month follow-up. This study was registered in the Chinese Clinical Trial Registry (ChiCTR) with the registration number ChiCTR2300076152 (registration date: September 26, 2023). Results: Baseline demographic and clinical characteristics were well balanced between the two groups (all P>0.05). After intervention, the observation group had a significant reduction in nodule diameter by 0.64 mm (95% CI: 0.20-1.08, P<0.01). Serum IL-6 decreased by 1.36 pg/mL (95% CI: 0.70-2.02, P<0.01), and peripheral blood neutrophil count decreased by 1.14×10 Conclusion: Within the limitations of this single-center, small-sample study with a 3-month follow-up, hydrogen-oxygen inhalation can reduce SPN diameter and downregulate peripheral blood IL-6 and neutrophil levels, exerting a targeted anti-inflammatory effect especially in smoking patients. It may serve as a safe non-invasive adjuvant intervention for SPNs, while further multicenter large-sample studies are needed to validate its general applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.